Alzheimer's Disease
Conditions
Brief summary
The primary objective of the study is to evaluate the safety and tolerability of single and multiple intravenous (IV) infusions of Aducanumab in Japanese participants with mild to moderate Alzheimer's Disease (AD). The secondary objectives of this study are as follows: To evaluate the serum pharmacokinetics (PK) of Aducanumab after single and multiple intravenous (IV) infusions of Aducanumab; To evaluate the effect of single and multiple IV infusions of Aducanumab on immunogenicity.
Interventions
DRUGAducanumab
As described in the treatment arm
DRUGPlacebo
IV administration of 0.9% sodium chloride
Sponsors
Biogen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
55 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Must be ambulatory * Must have a clinical diagnosis of mild to moderate AD * Must be in good health as determined by the Investigator, based on medical history and Screening assessments * Must have a caregiver who, understands the study and assents to accompany the subject to all study site visits, provide information to the Investigator/study site staff, specifically about cognitive abilities and AEs/SAEs and return for per-protocol follow-up visits and procedures * Must consent to blood sample collection for deoxyribonucleic acid (DNA; genotyping) and ribonucleic acid (RNA; for potential future analysis). Key
Exclusion criteria
* Any medical or neurological condition (other than AD) that in the opinion of the Investigator could be a contributing cause of the subject's dementia * Transient ischemic attack or stroke or any unexplained loss of consciousness within 1 year prior to Screening * Poorly controlled diabetes mellitus, as defined by having dosage adjustment of diabetic medication within the 3 months prior to Day 1 * History of unstable angina, myocardial infarction, chronic heart failure * Chronic, uncontrolled hypertension * History of seizure within 3 years prior to Screening * History within the past 6 months or evidence of clinically significant psychiatric illness * History of severe allergic or anaphylactic reactions, or history of hypersensitivity to any of the inactive ingredients in the drug product NOTE: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and nature of adverse events (AE) / serious adverse events(SAE) | Up to week 42 |
| Clinically significant changes in vital signs and 12-lead electrocardiogram (ECG) data; abnormalities in neurological and physical examinations | Up to week 42 |
| Brain magnetic resonance imaging (MRI) findings to assess amyloid-related imaging abnormalities (ARIA), including incidence of ARIA-E (edema) or ARIA-H (hemosiderosis) | Up to week 42 |
Secondary
| Measure | Time frame |
|---|---|
| Time to Cmax (Tmax) | Up to 8 weeks post dosing |
| Elimination half-life (t1/2) | Up to 8 weeks post dosing |
| Area under the concentration-time curve (AUC) from time zero extrapolated to infinity (AUC0-∞) | Up to 8 weeks post dosing |
| Clearance (CL) after a single IV infusion of aducanumab | Up to 8 weeks post dosing |
| Incidence of anti-aducanumab antibodies in serum | Up to week 42 |
| Volume of distribution at steady state (Vss) | Up to 8 weeks post dosing |
| AUC from time zero to time of the last measurable concentration (AUC0-last) | Up to 8 weeks post dosing |
| Maximum observed concentration (Cmax) | Up to 8 weeks post dosing |
Countries
Japan
Outcome results
None listed